Curated by Peter Schulte · Published 2026-08-20 · Last updated 2026-08-20
Mental health progress is no longer a distant promise — it’s arriving in measurable, historic waves.
Global suicide rates have fallen nearly 40% since the 1990s. Fentanyl overdose deaths in the U.S. dropped by a third in a single year. Psychedelic compounds once banned outright are now legal medicines in Australia, New Zealand, and a growing number of U.S. states.
The policy landscape is shifting just as fast. Decriminalization, record-clearing pardons, over-the-counter overdose reversal drugs, and landmark liability verdicts against social media platforms are reshaping how societies treat both addiction and mental illness.
Taken together, these advances represent the most consequential reorientation of mental health and drug policy in a generation — driven by science, advocacy, and a growing political consensus that punishment alone has never worked.
Key takeaways
- Global suicide rates have dropped nearly 40% since the 1990s — one of public health’s most underreported victories.
- Australia became the world’s first country to officially recognize psilocybin and MDMA as medicines; New Zealand, Colorado, New Mexico, and others have followed.
- Fentanyl overdose deaths in the U.S. fell roughly 35% in 2024 — the steepest single-year decline in the opioid epidemic’s history.
- Over-the-counter Narcan, brain circuit breakthroughs for opioid addiction, and a first-ever Alzheimer’s prevention trial signal a new era of evidence-based treatment.
- Cannabis legalization and decriminalization are now mainstream policy across Europe and the Americas, with mass pardons clearing hundreds of thousands of old convictions.
Recovery at a glance
| Subject | Recovery | Where |
|---|---|---|
| Global suicide rate | Down nearly 40% since the 1990s | Worldwide |
| Fentanyl overdose deaths (U.S.) | Fell ~35% in 2024; 112,000 → ~80,000 | United States |
| Psilocybin & MDMA as medicines | First country to officially authorize both | Australia |
| Psilocybin therapy | Approved for treatment-resistant depression | New Zealand |
| Phase 3 psilocybin trial | ~1,000-participant trial launched, first ever | Global (Compass Pathways) |
| Texas ibogaine research | $50 million state-funded program, largest in U.S. history | Texas, U.S. |
| New Mexico psilocybin therapy | Third U.S. state to legalize, via legislature | New Mexico, U.S. |
| Over-the-counter Narcan | First OTC opioid overdose reversal drug approved | United States |
| Maryland marijuana pardons | 175,000+ convictions cleared in one executive order | Maryland, U.S. |
| Golden Gate Bridge safety net | Jumps fell by more than half as net neared completion | San Francisco, U.S. |
| British Columbia drug decriminalization | First Canadian province to remove criminal penalties for possession | British Columbia, Canada |
| Luxembourg cannabis legalization | First European country to legalize home cannabis cultivation | Luxembourg |
| Malta cannabis legalization | First EU nation to legalize personal cultivation and use | Malta |
| Public support for psilocybin therapy | 91% of liberals, 86% of conservatives call it morally acceptable | United States |
| Alzheimer's prevention trial | Removing amyloid plaques cut disease risk by ~50% | United States |
| Social media liability verdict | First U.S. jury holds Meta and YouTube liable for youth mental harm | Los Angeles, U.S. |
On this page
- Why this matters
- What’s driving the comeback
- Psychedelic medicine: from clinical trials to legal treatment
- Psilocybin and psychedelic policy: U.S. states lead a legal revolution
- Cannabis legalization and the reckoning with prohibition’s legacy
- Opioid crisis reversal: overdose prevention and addiction science
- Suicide prevention and the global mental health reckoning
- Children’s mental health and the screen time reckoning
- Brain science and the future of prevention
- The outlook
- Frequently asked questions
Why this matters
For decades, mental health and drug policy were defined by criminalization, stigma, and under-investment. The evidence now points to a genuine inflection point — not incremental improvement, but structural change across multiple fronts simultaneously.
The numbers are striking. A 40% decline in global suicide rates. A 35% single-year drop in U.S. fentanyl deaths. Bipartisan supermajorities in multiple U.S. state legislatures voting to legalize psychedelic therapy. These are not isolated data points — they form a coherent pattern of progress.
What makes this moment different is the convergence of science, policy, and public opinion. Researchers have identified specific brain circuits driving opioid addiction. Regulators have granted psychedelics breakthrough status. And surveys show conservatives and liberals agreeing on the moral legitimacy of supervised psilocybin use at rates you rarely see on any issue.
By the numbers
- Global suicide rate fell from ~15 to ~9 deaths per 100,000 people since the early 1990s — a 40% decline.
- U.S. fentanyl overdose deaths dropped ~35% in 2024, from a peak of ~112,000 to an estimated 80,000.
- Maryland’s governor cleared 175,000+ marijuana convictions in a single executive order.
- 91% of U.S. liberals and 86% of conservatives consider supervised psilocybin therapy morally acceptable.
- Texas authorized $50 million for ibogaine research — the largest state-funded psychedelic program in U.S. history.
- Colorado’s Natural Medicine Health Act decriminalized psilocybin, DMT, ibogaine, and mescaline simultaneously.
- The Golden Gate Bridge safety net reduced the number of jumps by more than half as it neared completion.
What’s driving the comeback
The single clearest driver is the shift from punishment to care. British Columbia replaced arrest with referrals to health services for drug possession. New York’s first legal cannabis license went to a nonprofit serving the formerly incarcerated. Oregon built an entire regulated psilocybin facilitator system rather than simply decriminalizing. The harm reduction logic is the same in each case: criminal consequences don’t solve addiction or mental illness, but they do keep people from seeking help.
Scientific legitimacy has been the other accelerant. Australia’s authorization of psilocybin and MDMA as medicines was built on clinical evidence. Compass Pathways’ Phase 3 trial enrolled nearly 1,000 participants — the threshold required to move a compound toward regulatory approval. The FDA’s OTC authorization of Narcan, and researchers’ identification of the specific brain circuit driving fentanyl craving, show that the neuroscience is maturing fast enough to actually drive policy.
Bipartisan political will has repeatedly surprised observers. Texas — not a state associated with progressive drug policy — passed a $50 million ibogaine research bill with broad legislative support. New Mexico legalized psilocybin therapy through its legislature, not a ballot measure, with an overwhelming margin. This pattern suggests the change is durable, not dependent on a single political moment.
Psychedelic medicine: from clinical trials to legal treatment
The legalization of psychedelic therapy has moved faster in the past three years than in the previous five decades combined. What’s notable across these stories is the mechanism of change: it’s not just advocacy, but Phase 3 clinical trials, regulatory approvals, and legislative votes that are normalizing psilocybin, MDMA, and ibogaine as medical tools — not counterculture symbols.
Australia becomes the world’s first country to authorize psychedelics as medicines
Australia granted psychiatrists a legal pathway to prescribe psilocybin and MDMA as regulated treatments for PTSD and treatment-resistant depression — a global first. For patients who had exhausted every available conventional option, the decision opened an entirely new avenue of care.
New Zealand approves psilocybin therapy for treatment-resistant depression
New Zealand formally authorized supervised psilocybin therapy for severe, treatment-resistant depression, joining a small but growing group of nations to give the compound clinical legitimacy. The decision creates a legal framework for practitioners to administer the treatment under controlled conditions.
The world’s first Phase 3 psilocybin clinical trial launches
Compass Pathways launched the world’s first Phase 3 clinical trial for psilocybin in treatment-resistant depression, enrolling nearly 1,000 participants across two pivotal studies. Phase 3 is the evidentiary threshold a compound must clear to move toward full regulatory approval anywhere in the world.
First European psychedelic drug trial clinic opens in the U.K.
Clerkenwell Health’s opening moved psychedelic medicine from university labs into dedicated commercial infrastructure designed to carry compounds through late-stage clinical trials. Its first focus was patients facing terminal diagnoses — among the most compelling use cases for fast-tracked psychedelic research.
Psilocybin shown to help treat alcohol dependence in first-of-its-kind study
A study published in Psychology of Addictive Behaviors found that psilocybin-assisted therapy helped 13 people with heavy drinking histories reach the root causes of their alcohol use. Participants described years of self-blame and isolation quieting after their sessions — a qualitative signal that complements the growing clinical literature.
Texas launches the largest state psychedelic research program in U.S. history
The Texas Legislature passed HB 3717 with bipartisan support, authorizing $50 million for supervised clinical trials of ibogaine — a plant-derived compound long studied for its potential to interrupt addiction. The program is the largest state-funded psychedelic research initiative in U.S. history.
Psilocybin and psychedelic policy: U.S. states lead a legal revolution
What began in Oregon has become a genuine policy wave. Multiple U.S. states have now legalized or decriminalized psilocybin through both ballot measures and legislative votes, creating a patchwork of regulated access that is accumulating real infrastructure — licensed farms, trained facilitators, and operational service centers. Public opinion has moved in parallel, reaching rare bipartisan consensus.
Oregon approves the country’s first legal psilocybin mushroom farms
Satori Farms PDX became the first licensed psilocybin producer in the United States, ending more than 50 years of prohibition on legal cultivation. The farm planned to supply regulated service centers, marking the moment Oregon’s framework moved from policy to physical reality.
Oregon licenses its first-ever legal psilocybin facilitators
Oregon licensed its first three psilocybin facilitators in April 2023, formally authorizing practitioners to guide adults through psychedelic sessions at regulated service centers. More than 300 additional applicants were in the pipeline, indicating rapid buildout of the profession.
New Mexico becomes the third U.S. state to legalize psilocybin therapy
New Mexico’s Medical Psilocybin Act made the state the third in the U.S. to legalize psilocybin therapy — and its path was distinctive: the legislation passed through the state legislature with an overwhelming bipartisan margin, not a ballot measure. That route signals broader political mainstreaming than a narrow referendum win would have.
Colorado voters pass the most expansive psychedelic decriminalization law in U.S. history
Colorado’s Natural Medicine Health Act removed criminal penalties for the personal use of psilocybin, DMT, ibogaine, and mescaline simultaneously — going further than any previous state psychedelic law. Alongside decriminalization, the act established a licensed therapy clinic system, combining harm reduction with regulated access.
Nearly 9 in 10 Americans now view supervised psilocybin therapy as morally acceptable
A peer-reviewed survey of 795 U.S. adults found that 91% of liberals and 86% of conservatives considered supervised psilocybin therapy for psychiatric treatment morally acceptable. That level of bipartisan agreement on a drug policy question is historically anomalous and suggests a durable political foundation for continued reform.
Cannabis legalization and the reckoning with prohibition’s legacy
Cannabis legalization has moved from the political fringe to mainstream governance, but the most significant developments are no longer just about legalization itself — they’re about repair. Record-clearing pardons, equity-focused licensing, and the dismantling of criminal records are becoming standard features of cannabis reform, reflecting a broader reckoning with who bore the costs of prohibition.
Luxembourg becomes the first European country to legalize home cannabis cultivation
Luxembourg allowed adults 18 and over to grow up to four cannabis plants at their primary residence, becoming the first country in Europe to take this step. Possession of up to three grams was simultaneously downgraded from a criminal offense to a minor infraction.
Malta becomes the first EU nation to fully legalize personal cannabis use
Malta’s parliament passed cannabis legalization by a vote of 36 to 27, allowing adults to grow up to four plants at home and carry small amounts without criminal charges. The law also established regulated nonprofit associations, creating a social framework alongside personal freedoms.
Germany moves to become the second EU nation to legalize recreational cannabis
Germany’s proposed legalization would allow licensed shops and pharmacies to sell cannabis — a major shift for Europe’s largest economy and a signal that prohibition’s dominance in Europe was ending. The country’s own health minister acknowledged that prohibition had shown no clear results.
New York’s first legal cannabis dispensary opens — with an equity-first license
New York’s first legal recreational cannabis dispensary was awarded to Housing Works, a nonprofit serving people with HIV, homeless New Yorkers, and the formerly incarcerated. Revenue flows back into those communities, making the opening a direct reinvestment of cannabis proceeds into the populations most harmed by its criminalization.
Minnesota becomes the 23rd U.S. state to legalize recreational marijuana — and clears tens of thousands of convictions
Minnesota paired cannabis legalization with one of the country’s most ambitious record-clearing efforts, automatically expunging tens of thousands of low-level marijuana convictions. Governor Tim Walz signed the law, which allows adults 21 and older to possess cannabis.
Maryland governor issues 175,000 pardons for marijuana convictions — a national record
Governor Wes Moore signed the largest state-level pardon in U.S. history, clearing more than 175,000 marijuana convictions in a single executive order. Moore framed it as completing the unfinished work of legalization — acknowledging that decriminalizing future conduct without addressing past punishment is an incomplete reform.
Opioid crisis reversal: overdose prevention and addiction science
The opioid epidemic’s trajectory has shifted — not by accident, but through a combination of harm reduction policy, new pharmacological tools, and neuroscience that is finally identifying the specific mechanisms driving addiction. The challenge now is whether the infrastructure built during the crisis can be sustained and scaled as the acute emergency recedes.
Fentanyl overdose deaths fall by a third in the steepest single-year drop in epidemic history
Provisional CDC data showed U.S. drug overdose deaths falling from a peak of roughly 112,000 in 2023 to an estimated 80,000 in 2024 — a drop of approximately 35%. It was the steepest single-year decline in the history of the opioid epidemic, though the absolute toll remained devastating.
FDA approves over-the-counter Narcan — the first OTC opioid overdose reversal drug in U.S. history
The FDA cleared the 4 mg naloxone nasal spray for sale at pharmacies, convenience stores, and other retailers without a prescription, making it the first opioid overdose reversal drug ever to earn OTC status. Naloxone works within minutes of a fentanyl overdose, and removing the prescription barrier was a direct harm reduction intervention.
Scientists identify the specific brain circuit driving fentanyl addiction — opening a new treatment target
Researchers identified a discrete brain circuit responsible for the emotional crash — anxiety, depression, craving — that traps people in the fentanyl cycle even after they stop using. The discovery gives scientists and drug developers a concrete neurological mechanism to target, rather than treating addiction as a diffuse behavioral problem.
British Columbia becomes the first Canadian province to decriminalize possession of hard drugs
British Columbia replaced criminal penalties for personal drug possession with referrals to care — one of the most significant public health pivots in Canadian history. The policy rested on a clear finding: fear of police was keeping people from calling for help during overdoses, and criminalization was actively worsening outcomes.
Suicide prevention and the global mental health reckoning
The global decline in suicide rates is one of public health’s most underreported achievements — and the stories here illustrate the range of interventions that work, from physical infrastructure to expanded crisis services. What connects them is a shift from fatalism to engineering: treating suicidality as a solvable problem rather than an inevitable tragedy.
Global suicide rate has dropped nearly 40% since the 1990s
Suicide rates fell from roughly 15 deaths per 100,000 people in the early 1990s to around 9 — a nearly 40% decline driven by expanded mental health services, crisis intervention, and means restriction. It is one of modern public health’s most significant and least-celebrated victories.
The Golden Gate Bridge suicide prevention net is complete — and it’s already working
A continuous stainless steel safety net, suspended 20 feet below the bridge deck across the full 1.7-mile span, was completed in the Golden Gate project. As the net neared completion in 2023, the number of people who jumped fell by more than half — direct evidence that physical means restriction saves lives.
Children’s mental health and the screen time reckoning
A growing body of policy is now targeting the structural conditions shaping young people’s mental health — particularly smartphone and social media exposure. What’s notable is the shift from individual advice to binding law: governments and juries are placing responsibility on institutions rather than on children or their parents.
Brazil bans smartphones in schools nationwide — and early results are striking
Brazil’s national school smartphone ban showed early effects in Stanford-led research: 83% of students across all 26 states reported paying more attention in class following the policy. The results added empirical weight to a global push to restructure the school day around learning rather than devices.
New Jersey enacts a landmark all-day school phone ban affecting 1.4 million students
New Jersey’s law requires all K–12 public schools to adopt phone-free policies before the 2025 school year, covering nearly 1.4 million students. Students must store devices in pouches, lockers, or designated areas throughout the school day — one of the most comprehensive such mandates in the U.S.
Australia bans social media for children under 16 — and holds platforms responsible
Australia’s law placed responsibility for enforcing the under-16 social media ban squarely on platforms, with fines reaching AUD $50 million for companies that repeatedly allow underage users through. Passed with strong cross-party support, the law gave major platforms a deadline to build compliant age-verification systems.
Los Angeles jury holds Meta and YouTube liable for harming youth mental health — a legal first
A Los Angeles jury found Meta and YouTube legally responsible for psychological damage to minors — the first time a U.S. jury has held major social media platforms liable for youth mental health harms. Attorneys successfully argued that the platforms’ design choices caused measurable psychological harm to young users.
Brain science and the future of prevention
Behind the policy shifts sits a rapidly advancing scientific frontier — from Alzheimer’s prevention trials to neuroscience that is mapping the brain circuits underlying addiction. These findings matter not just as laboratory milestones but as the evidence base that will determine which treatments receive regulatory approval and public funding in the years ahead.
Landmark Alzheimer’s trial cuts disease risk by half through early intervention
A trial at Washington University School of Medicine found that removing amyloid plaques before symptoms appear cut the risk of developing Alzheimer’s disease by roughly 50%. The study focused on people with rare genetic markers for early-onset disease, offering the first proof-of-concept that prevention, not just treatment, is achievable.
The outlook
The trajectory is clearly positive, but fragile in specific ways. Psychedelic therapy access remains limited to those who can afford supervised clinical settings. Decriminalization in British Columbia was a pilot, not a permanent fixture. And the U.S. fentanyl decline, while historic, still represents roughly 80,000 deaths in a single year.
The Alzheimer’s prevention trial result — cutting disease risk by half through early amyloid removal — hints at a broader principle: intervening before crisis, not after, is where the biggest gains lie. The same logic applies across mental health: suicide nets, early psilocybin access, OTC naloxone, school phone bans. Prevention scales in ways that crisis response cannot.
What determines whether momentum continues is largely institutional: whether regulators move at the speed the science justifies, whether legal cannabis revenue is reinvested in the communities most harmed by prohibition, and whether the social media liability verdict in Los Angeles marks the beginning of platform accountability or a one-off anomaly. The wins are real. Whether they compound depends on choices still being made.
Frequently asked questions
What is driving global mental health progress right now?
Three forces are converging: a shift in drug policy from criminalization to harm reduction, rapid advances in psychedelic medicine backed by clinical trials, and new neuroscience identifying specific brain mechanisms behind addiction and depression. Global suicide rates have dropped nearly 40% since the 1990s, and U.S. fentanyl overdose deaths fell roughly 35% in a single year — signs that evidence-based approaches are scaling.
Which countries have legalized psilocybin therapy?
Australia was the first country to officially authorize psilocybin (and MDMA) as regulated medicines, allowing psychiatrists to prescribe them for PTSD and treatment-resistant depression. New Zealand followed with approval of supervised psilocybin therapy for severe, treatment-resistant depression. In the U.S., Oregon, Colorado, and New Mexico have legalized psilocybin therapy at the state level, with Texas funding the largest state psychedelic research program in U.S. history.
How much have fentanyl overdose deaths declined in the U.S.?
Fentanyl overdose deaths dropped by roughly 35% in 2024 — the steepest single-year decline in the opioid epidemic’s history. Provisional CDC data showed total drug overdose deaths falling from a peak of around 112,000 in 2023 to an estimated 80,000 in 2024. Over-the-counter Narcan access and decriminalization policies like British Columbia’s are among the factors credited with improving outcomes.
Does the Golden Gate Bridge safety net actually reduce suicides?
Yes. As the stainless steel safety net neared completion in 2023, the number of people who jumped from the bridge fell by more than half. The net runs the full 1.7-mile span, suspended 20 feet below the deck. It is one of the clearest real-world demonstrations of the ‘means restriction’ principle in suicide prevention.
What U.S. states have passed the largest marijuana pardons?
Maryland set the national record when Governor Wes Moore cleared more than 175,000 marijuana convictions in a single executive order — the largest state-level pardon any U.S. governor has signed. Minnesota paired its 2023 cannabis legalization with automatic expungement of tens of thousands of low-level marijuana convictions, one of the most ambitious record-clearing efforts in the country.
How does removing criminal penalties for drug possession help reduce overdoses?
British Columbia’s decriminalization was premised on a documented problem: fear of police was keeping people from calling for help during overdoses. By replacing arrest with referrals to care for adults carrying small amounts of certain substances, the policy removed a barrier that was actively worsening outcomes. The same logic underpins over-the-counter Narcan — reducing friction between someone in crisis and the tool that can reverse an overdose.
About this article
🤖 This article is AI-generated, based on a framework created by Peter Schulte.
🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
